Shazia Ali, MD
Gastroenterology · Laguna Hills
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Healthcare Partners Affiliates Medical Group · 775 clinicians in this group
Looking this up.
Hospitals listed: Memorialcare Saddleback Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Ali’s office at (949) 588-8700 to ask if they take your plan before you enroll.
California Medical Board record
Licence A108661 · Current
Licensed to practise in California · since 2009 · expires 2027-01-31 · University of California, San Diego School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Memorialcare Saddleback Medical CenterLaguna Hills, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of MemorialCare Health System, which runs 4 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 4 of 5 starsNo measure marked better or worse than the national rate
See every measure and the patient survey for Memorialcare Saddleback Medical Center
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 0 better, 6 the same, 0 worse of 6 measures. Readmissions: 2 better, 5 the same, 0 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.88 (0 to 1.88) · 787 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.98 (0.64 to 1.32) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 150.94 (98.19 to 203.69) · 56 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 26 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 9.2 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.2 · 112 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 330 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.7 · 288 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.1 · 322 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.5 · 3,096 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.21 (0 to 0.42) · 4,618 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.07 to 0.46) · 4,715 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.39 (1.23 to 5.56) · 1,071 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.88 (0.26 to 3.5) · 374 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.86 (0.31 to 3.41) · 983 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 14.09 (6.81 to 21.36) · 364 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.33 (1.61 to 9.05) · 376 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.18 to 3.17) · 254 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.19 (0 to 0.92) · 3,414 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 40 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.488 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.676 | No different | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.833 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.49 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.344 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.8 · 222 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.2 · 693 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -27.3 · 122 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -26.7 · 401 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 19.4 · 308 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.6 · 517 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.2 · 30 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10 · 66 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.8 · 228 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.4) · 325 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,973 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 73% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
Procedures Medicare counted
| Colonoscopy | 43 | More than 60% of doctors who do this |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 24 | More than 53% of doctors who do this |
Drugs they prescribed that Part D paid
$140,915
Pharmacies billed $140,915 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 130) in 2024. At or below the middle of the specialty; the typical gastroenterology clinician is at 0%.
102 generic and 28 brand-name prescriptions · $140,915 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Gavilyte-C | 39 | $871 | $22 |
| Omeprazole | 11 | $126 | $11 |
Year by year
| 2024 | 130 | 67 | 0% (0) | 22% | $140,915 |
| 2023 | 201 | 114 | 0% (0) | 28% | $281,243 |
| 2022 | 161 | 91 | 0% (0) | 25% | $77,522 |
| 2021 | 93 | 63 | 0% (0) | 40% | $90,165 |
| 2020 | 164 | 81 | 0% (0) | 35% | $199,036 |
| 2019 | 173 | 98 | 0% (0) | 36% | $83,433 |
| 2018 | 325 | 192 | 0% (0) | 44% | $147,912 |
| 2017 | 536 | 346 | 0% (0) | 22% | $159,663 |
| 2016 | 415 | 302 | 0% (0) | 18% | $190,053 |
| 2015 | 302 | 197 | 0% (0) | 17% | $103,687 |
| 2014 | 270 | 169 | 0% (0) | 24% | $66,975 |
| 2013 | 148 | 95 | 0% (0) | 7% | $17,627 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 2 drugs
| Gavilyte-C | 75 | $1,553 | $21 |
| Peg-3350 and Electrolytes | 12 | $322 | $27 |
2022: 6 drugs
| Lialda | 11 | $5,660 | $515 |
| Balsalazide Disodium | 15 | $5,465 | $364 |
| Ursodiol | 11 | $2,617 | $238 |
| Gavilyte-C | 44 | $795 | $18 |
| Peg-3350 and Electrolytes | 18 | $408 | $23 |
| Omeprazole | 20 | $136 | $7 |
2021: 2 drugs
| Peg-3350 and Electrolytes | 16 | $359 | $22 |
| Gavilyte-C | 19 | $285 | $15 |
2020: 4 drugs
| Xifaxan | 14 | $37,883 | $2,706 |
| Balsalazide Disodium | 18 | $6,841 | $380 |
| Gavilyte-C | 33 | $599 | $18 |
| Azathioprine | 11 | $507 | $46 |
2019: 3 drugs
| Xifaxan | 20 | $38,939 | $1,947 |
| Balsalazide Disodium | 11 | $3,119 | $284 |
| Gavilyte-C | 53 | $1,967 | $37 |
2018: 5 drugs
| Xifaxan | 44 | $92,022 | $2,091 |
| Balsalazide Disodium | 26 | $9,183 | $353 |
| Gavilyte-C | 92 | $3,393 | $37 |
| Peg 3350-Electrolyte | 57 | $2,188 | $38 |
| Omeprazole | 15 | $211 | $14 |
2017: 7 drugs
| Xifaxan | 41 | $77,151 | $1,882 |
| Balsalazide Disodium | 16 | $5,807 | $363 |
| Gavilyte-C | 312 | $5,448 | $17 |
| Twinrix | 12 | $1,032 | $86 |
| Spironolactone | 24 | $473 | $20 |
| Omeprazole | 17 | $223 | $13 |
| Furosemide | 14 | $158 | $11 |
2016: 5 drugs
| Xifaxan | 21 | $39,952 | $1,902 |
| Balsalazide Disodium | 16 | $15,225 | $952 |
| Gavilyte-C | 266 | $4,666 | $18 |
| Omeprazole | 17 | $248 | $15 |
| Peg 3350-Electrolyte | 11 | $187 | $17 |
2015: 6 drugs
| Lialda | 15 | $31,811 | $2,121 |
| Xifaxan | 14 | $28,412 | $2,029 |
| Balsalazide Disodium | 13 | $12,435 | $957 |
| Gavilyte-C | 162 | $2,958 | $18 |
| Omeprazole | 17 | $311 | $18 |
| Pantoprazole | 12 | $236 | $20 |
2014: 5 drugs
| Lialda | 27 | $43,987 | $1,629 |
| Gavilyte-C | 114 | $2,046 | $18 |
| Peg 3350-Electrolyte | 25 | $461 | $18 |
| Omeprazole | 25 | $422 | $17 |
| Pantoprazole | 20 | $385 | $19 |
2013: 3 drugs
| Gavilyte-C | 75 | $1,335 | $18 |
| Omeprazole | 22 | $517 | $23 |
| Pantoprazole | 14 | $241 | $17 |
Money from drug and device companies
$483 in 2025
A payment is not proof that care is biased.
| Genzyme | Dupixent | $183 | 2 payments
|
| Madrigal Pharmaceuticals | Rezdiffra | $134 | 3 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $79 | 4 payments
|
| Abbvie | Skyrizi | $67 | 3 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $20 | 1 payment
|
See all 13 published payments
| Madrigal Pharmaceuticals | Meals · 2025-12-03 | Rezdiffra | $46 |
| Abbvie | Meals · 2025-11-20 | Rinvoq | $26 |
| Genzyme | Meals · 2025-11-03 | Dupixent | $33 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-08-18 | Entyvio | $19 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-08-14 | Entyvio | $23 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-08-12 | Entyvio | $18 |
| Abbvie | Meals · 2025-07-07 | Skyrizi | $20 |
| Abbvie | Meals · 2025-06-16 | Skyrizi | $21 |
| Madrigal Pharmaceuticals | Meals · 2025-06-02 | Rezdiffra | $42 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-05-27 | Xifaxan | $20 |
| Madrigal Pharmaceuticals | Meals · 2025-05-19 | Rezdiffra | $46 |
| Genzyme | Meals · 2025-04-17 | Dupixent | $150 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-01-30 | Entyvio | $19 |
Professional record
- NPI
- 1063616217
- Licence
- CA A108661, OR LL16591California A108661: Current · expires 2027-01-31
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RG0100X (207RG0100X); Student in a training program (390200000X)
- Mailing address
- Po Box 35380, Las Vegas, NV, 89133
- NPI first listed
- 2007-06-12
- NPI last updated
- 2025-11-14
- NPI record certified
- 2025-11-14
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 23521 Paseo De Valencia Ste 311, Laguna Hills, CA, 92653 · 270 International Cir, San Jose, CA, 95119
This office lists an electronic records connection.